Loading...

Christopher Carpenter

TitleHS CLIN INSTR-HCOMP
SchoolUCSF School of Medicine
DepartmentPediatrics
Address505 Parnassus Avenue
San Francisco CA 94117
Phone415-476-5001
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Global Health

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Carpenter CL, Cuellar TA, Friel MT. Reply: Office-Based Postaxial Polydactyly Excision in Neonates, Infants, and Children. Plast Reconstr Surg. 2017 01; 139(1):318e. PMID: 28027268.
      View in: PubMed
    2. Carpenter CL, Cuellar TA, Friel MT. Reply to correspondence: Office-Based Post-Axial Polydactyly Excision in Neonates, Infants, and Children. Plast Reconstr Surg. 2016 Sep 16. PMID: 27643419.
      View in: PubMed
    3. Gilan O, Lam EY, Becher I, Lugo D, Cannizzaro E, Joberty G, Ward A, Wiese M, Fong CY, Ftouni S, Tyler D, Stanley K, MacPherson L, Weng CF, Chan YC, Ghisi M, Smil D, Carpenter C, Brown P, Garton N, Blewitt ME, Bannister AJ, Kouzarides T, Huntly BJ, Johnstone RW, Drewes G, Dawson SJ, Arrowsmith CH, Grandi P, Prinjha RK, Dawson MA. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016 Jul; 23(7):673-81. PMID: 27294782.
      View in: PubMed
    4. Van Aller GS, Graves AP, Elkins PA, Bonnette WG, McDevitt PJ, Zappacosta F, Annan RS, Dean TW, Su DS, Carpenter CL, Mohammad HP, Kruger RG. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 03; 24(5):774-781. PMID: 27066749.
      View in: PubMed
    5. Carpenter CL, Cuellar TA, Friel MT. Office-Based Post-Axial Polydactyly Excision in Neonates, Infants, and Children. Plast Reconstr Surg. 2016 Feb; 137(2):564-8. PMID: 26818291.
      View in: PubMed
    6. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, Bonnette WG, Gorman SA, Degenhardt Y, Bai Y, McCabe MT, Pappalardi MB, Kasparec J, Tian X, McNulty KC, Rouse M, McDevitt P, Ho T, Crouthamel M, Hart TK, Concha NO, McHugh CF, Miller WH, Dhanak D, Tummino PJ, Carpenter C, Johnson NW, Hann CL, Kruger RG. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13; 28(1):57-69. PMID: 26175415.
      View in: PubMed
    7. Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, Deen K, Carpenter C, Benson P, Ho TH, Pandite L, de Souza P, Powles T, Motzer RJ. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2015 Mar 01; 21(5):1071-7. PMID: 25538263.
      View in: PubMed
    8. Lauriol J, Keith K, Jaffré F, Couvillon A, Saci A, Goonasekera SA, McCarthy JR, Kessinger CW, Wang J, Ke Q, Kang PM, Molkentin JD, Carpenter C, Kontaridis MI. RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis. Sci Signal. 2014 Oct 21; 7(348):ra100. PMID: 25336613; PMCID: PMC4300109.
    9. Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013 Sep 15; 19(18):5218-26. PMID: 23881929; PMCID: PMC4522695.
    10. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter C, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013 Aug; 14(9):882-92. PMID: 23810788.
      View in: PubMed
    11. Wilkins A, Carpenter C. Regulation of RhoBTB2 by the Cul3 ubiquitin ligase complex. Methods Enzymol. 2008; 439:103-9. PMID: 18374159.
      View in: PubMed
    12. Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter C, Balk SP. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem. 2007 Nov 09; 282(45):32689-98. PMID: 17823122.
      View in: PubMed
    13. Perez-Mansilla B, Ha VL, Justin N, Wilkins AJ, Carpenter C, Thomas GM. The differential regulation of phosphatidylinositol 4-phosphate 5-kinases and phospholipase D1 by ADP-ribosylation factors 1 and 6. Biochim Biophys Acta. 2006 Dec; 1761(12):1429-42. PMID: 17071135.
      View in: PubMed
    14. Saci A, Carpenter C. RhoA GTPase regulates B cell receptor signaling. Mol Cell. 2005 Jan 21; 17(2):205-14. PMID: 15664190.
      View in: PubMed
    15. Yang SA, Carpenter C, Abrams CS. Rho and Rho-kinase mediate thrombin-induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets. J Biol Chem. 2004 Oct 01; 279(40):42331-6. PMID: 15277528.
      View in: PubMed
    16. Wilkins A, Ping Q, Carpenter C. RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex. Genes Dev. 2004 Apr 15; 18(8):856-61. PMID: 15107402; PMCID: PMC395845.
    17. Chang JD, Field SJ, Rameh LE, Carpenter C, Cantley LC. Identification and characterization of a phosphoinositide phosphate kinase homolog. J Biol Chem. 2004 Mar 19; 279(12):11672-9. PMID: 14701839.
      View in: PubMed
    18. Saito K, Tolias KF, Saci A, Koon HB, Humphries LA, Scharenberg A, Rawlings DJ, Kinet JP, Carpenter C. BTK regulates PtdIns-4,5-P2 synthesis: importance for calcium signaling and PI3K activity. Immunity. 2003 Nov; 19(5):669-78. PMID: 14614854.
      View in: PubMed
    19. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter C, Kwiatkowski DJ. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest. 2003 Oct; 112(8):1223-33. PMID: 14561707; PMCID: PMC213485.
    20. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003 Jul; 40(3):244-56. PMID: 12876673.
      View in: PubMed
    21. Barkalow KL, Falet H, Italiano JE, van Vugt A, Carpenter C, Schreiber AD, Hartwig JH. Role for phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change. Am J Physiol Cell Physiol. 2003 Oct; 285(4):C797-805. PMID: 12788695.
      View in: PubMed
    22. Marks SS, Watson DL, Carpenter C, Messing RO, Greenberg DA. Comparative effects of chronic exposure to ethanol and calcium channel antagonists on calcium channel antagonist receptors in cultured neural (PC12) cells. J Neurochem. 1989 Jul; 53(1):168-72. PMID: 2470859.
      View in: PubMed
    23. Marks SS, Watson DL, Carpenter C, Messing RO, Greenberg DA. Calcium channel antagonist receptors in cerebral cortex from alcoholic patients. Brain Res. 1989 Jan 23; 478(1):196-8. PMID: 2538202.
      View in: PubMed
    24. Watson DL, Carpenter C, Marks SS, Greenberg DA. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease. Ann Neurol. 1988 Mar; 23(3):303-5. PMID: 2967667.
      View in: PubMed
    25. Carpenter C, Marks SS, Watson DL, Greenberg DA. Dextromethorphan and dextrorphan as calcium channel antagonists. Brain Res. 1988 Jan 26; 439(1-2):372-5. PMID: 2451974.
      View in: PubMed
    Christopher's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP